SGNX just went thru past month 10-k:
1. 352,942 shares been bought by SciClone for approximately $8.50 per share, for an aggregate price of $3,000,000 ( September 9, 2016) they might buy more.
2. As of December 31, 2016, we had 19 full-time employees, 8 of whom are MDs/PhDs.
3. As of December 31, 2016, we had cash and cash equivalents of
$8,772,567 as compared to $4,921,545 as of December 31, 2015,
representing an increase of $3,851,022 or 78%. The increase in cash was primarily the result of net proceeds received from financing activities in 2016 of
$8,840,602, primarily from a public offering of our stock and our stock purchase agreement with
SciClone Pharmaceuticals, Inc. This was partially offset by cash
used in operations of $4,982,421. As of December 31, 2016, we had working capital of $7,243,918 as compared to working capital of $2,179,694, which excludes a non-cash warrant liability of $2,434,101, as of December 31, 2015, representing an increase of $5,064,224 or 232%. The increase in working capital was primarily the result of the cash received from our financing activities.
4.We have up to $17.3 million in active contract funding still available to support our associated research programs in 2017 and beyond, provided the federal agencies exercise all options and do not elect to terminate the contracts for convenience. We plan to submit additional
contract and grant applications for further support of these programs with various funding agencies;
5. As of December 31,2016 : Total assets, $10.2m ($8.7m Cash), Total Liabilities $2.2m
Outstanding Shares
5,472,532
a/o Mar 17, 2017
My posts are my opinion and should not be used as investment advice. Make your own decisions in your stock trades.
